Clinical Trials
50 trialsFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
RAINFOL-01
Genmab
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
NEC Bio B.V
SIMONE
Yale University
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
OP-NEU-101
Onchilles Pharma Inc
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Cedars-Sinai Medical Center
ELUCIDATE
Exscientia AI Limited
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
SELECT-2CAR
Beijing Biotech
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Beijing Biotech
BetaBart
Radiopharm Theranostics, Ltd
DUAL-NK-BC
Beijing Biotech
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Gilead Sciences
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics Ltd
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics, Inc.
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Strand Therapeutics Inc.
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
ModiFY
Scancell Ltd
DENALI-1
A2 Biotherapeutics Inc.
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
ProDa BioTech, LLC
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
ComPACT
National University Hospital, Singapore
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
ABILITY-1
Medicenna Therapeutics, Inc.
4CAST
St Vincent's Hospital, Sydney
CIRCADIAN
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
BAH249
Essen Biotech
CTS2190 Phase I /II Clinical Study in Patients
CytosinLab Therapeutics Co., Ltd.
COMPASS-TNBC
Gustave Roussy, Cancer Campus, Grand Paris
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
CURATE
Cancer Research UK
TILS001
Fundacio Clinic Barcelona
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Jiangxi Provincial Cancer Hospital